Your Health, We Care
Finerenone is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
来自FDA，2022.09
Finerenone is applicable to chronic kidney disease related to type 2 diabetes.【more】
Article source：Lucius LaosRelease date：2026-01-06Recommended：17
This article analyzes the clinical application and economic cost of finerenone.What are the suitable populations for finerenone?The use of this drug should be strictly in accordanc···【more】
Article source：Lucius LaosRelease date：2025-04-15Recommended：184
According to the treatment needs of patients with specific chronic diseases, the application value of finerenone has gradually attracted attention.What diseases is finerenone suita···【more】
Article source：Lucius LaosRelease date：2025-04-15Recommended：167
In view of the application value and clinical practice of finerenone, this article reviews the key information.What are the indications for finerenoneThis drug has shown a unique r···【more】
Article source：Lucius LaosRelease date：2025-04-14Recommended：127
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
